Achillion Pharmaceuticals (NASDAQ:ACHN) Issues Quarterly Earnings Results

Achillion Pharmaceuticals (NASDAQ:ACHN) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02, Fidelity Earnings reports.

ACHN opened at $6.36 on Friday. Achillion Pharmaceuticals has a one year low of $1.29 and a one year high of $6.46. The company’s 50 day simple moving average is $4.93 and its 200-day simple moving average is $3.79. The stock has a market capitalization of $888.45 million, a P/E ratio of -12.47 and a beta of 1.67.

ACHN has been the topic of several research analyst reports. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 price objective on the stock. in a research note on Tuesday, August 27th. Leerink Swann cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.30 price target on the stock. in a research note on Friday, October 18th. ValuEngine raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. BidaskClub cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 12th. Finally, JMP Securities cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $4.96.

In other news, CEO Joseph Truitt sold 133,484 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $6.37, for a total transaction of $850,293.08. Following the sale, the chief executive officer now directly owns 103,734 shares of the company’s stock, valued at $660,785.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.58% of the stock is owned by corporate insiders.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Article: What is the Beige Book?

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.